Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. Issue 4 (August 2019)

• Record Type: Journal Article
• Authors: Bafaloukos, Dimitrios; Papaxoinis, George; Linardou, Helena; Diamantopoulos, Panagiotis; Laskarakis, Apostolos; Anastasopoulou, Amalia; Sergentanis, Theodoros N.; Tarampikou, Anthi; Tsoutsos, Dimosthenis; Gogas, Helen
• Is Part Of: Melanoma research. Volume 29:Issue 4(2019)
• Publication Date: 2019-08
• Subjects: BRAF inhibitors -- distant metastasis-free interval -- MEK inhibitors -- melanoma -- postrelapse survival -- prognosis; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000562
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : This retrospective cohort study assessed the prognostic significance of distant metastasis-free interval (DMFI) in patients with relapsed BRAF-mutant melanoma treated with BRAF with or without MEK inhibitors (BRAFi ± MEKi). Patients with a DMFI of up to 24 months were compared with those with DMFI of more than 24 months, with regard to their postrelapse progression-free survival (PR-PFS) and overall survival (PR-OS). In total, 109 patients were included in the study. Median DMFI was 25.3 (range: 3.4–188.2) months. Median PR-PFS in patients with DMFI of more than 24 months was 7.9 months [95% confidence interval (CI): 6.2–9.7] compared with 5.4 (95% CI: 4.2–6.7) months of those with shorter DMFI ( P = 0.016). Median PR-OS was 15.6 months (95% CI: 13.6–17.6) in patients with DMFI of more than 24 months and 12.0 months (95% CI: 9.0–15.0) with DMFI of up to 24 months ( P = 0.289). Multivariate Cox regression analysis showed that DMFI was independently and strongly associated with improved PR-PFS (adjusted hazard ratio = 3.21, 95% CI: 1.78–5.77, ⩽ 24 vs. > 24 months) and longer PR-OS (adjusted hazard ratio: 2.09, 95% CI: 1.15–3.80, ⩽ 24 vs. > 24 months). The present cohort study is one of the first to confirm the association of DMFI of more than 24 months with an indolent disease course, as shown by longer PR-PFS and PR-OS, in patients with relapsed stage IV melanoma treated by BRAF inhibitor/MEK inhibitor. Abstract : Supplemental Digital Content is available in the text.